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Primary Neuroendocrine Tumours (NETs) of the gallbladder are rare. Among all NETs of the gallbladder,
large cell neuroendocrine carcinoma (LCNEC) is exceedingly rare. In most of the cases LCNECs are
combined with other histological components. We reviewed clinical presentation and management of all
patients with “pure” LCNEC from published literature since the ﬁrst case was published in 2000, as well
as one patient from our experience. Only 7 cases of “pure” LCNEC has been described in the last 15 years,
our case is the eighth. The diagnosis of gallbladder NETs is rarely made preoperatively since the pre-
sentation generally consists of non-speciﬁc symptoms including upper abdominal pain, discomfort,
jaundice, weight loss. The majority of patients are identiﬁed incidentally at the time of cholecystectomy
for cholelithiasis. It is not possible to differentiate preoperatively between gallbladder adenocarcinoma
and gallbladder neuroendocrine carcinoma (NEC) with imaging techniques. The only curative therapeutic
modality for LCNECs is a complete en bloc surgical resection, including regional lymph node clearances
and hepatic lobectomy, but only in patients without multiple metastasis. LCNECs beneﬁt from an
aggressive surgical resection in combination with chemotherapy, if resectability is possible. If the tumour
is non-resectable, the primary management is therefore medical and not surgical. All patients with
LCNEC presented a poor prognosis with a median survival of 10 months after the initial diagnosis. Only in
ﬁve patients (62.5%) a wide surgical excision was performed, while in the other cases the tumour was
non-resectable or multiple liver metastases were present at diagnosis.
© 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.1. Introduction
Primary Neuroendocrine Tumours (NETs) of the gallbladder are
particularly rare, accounting for 0.5% of all NETs and 2.1% of all
gallbladder cancers. They are more frequent in females (68%) and
the age at presentation ranges from 25 to 85 years peaking in ages
75e79 years [1]. It seems plausible that the neuroendocrine cell
origin for gallbladder NENs is either an undifferentiated stem cell or
a mucosal neuroendocrine cell in the background of chronic in-
ﬂammatory induced intestinal or/and gastric metaplasia leading toncological and Dentistry Sci-
Buscemi).
ished by Elsevier Ltd. All rights resmalignant transformation [2]. The current WHO classiﬁcation di-
vides neuroendocrine neoplasms of the gallbladder into the cate-
gories of neuroendocrine tumour (NET G1 and G2), small cell
neuroendocrine carcinoma (SCNEC), large cell neuroendocrine
carcinoma (LCNEC), mixed adenoneuroendocrine carcinoma
(MANEC), goblet cell carcinoid and tubular carcinoid [3]. Among all
NETs of the gallbladder, LCNECs are exceedingly rare [2], the ﬁrst
case reported in 2000 [4]. In most of the cases LCNECs are com-
bined with other histological components, including adeno-, ade-
nosquamous and mucinous carcinoma [5] To the best of our
knowledge the case we report is the eighth case of a pure form of
primary gallbladder LCNEC (GB-LCNEC), incidentally found at
cholecystectomy in a 76-year-old woman. We also performed the
review of all the cases of pure GB-LCNEC, as shown in Table 1.erved.
Table 1
Clinical features of 8 pure large cell neuroendocrine carcinomas of gallbladder: CHO, cholecystectomy; Chemo, chemotherapy; Chemo NS, chemotherapy administered, but
drugs not speciﬁed; CisP, cisplatin; CarP, carboplatin; ETP, etoposide; CAV, cyclophosphamide adriamycin vincristine; CY,; DTX, docetaxel; LR, liver resection; LN, lymphnodes;
3D-RT, three-dimensional radiation therapy; CBD, common bile duct; LY, lymphadenectomy; FNA, ﬁne needle aspiration; mths, months; wks, weeks; yrs, years; pt, patient.
Author
[ref.]
Sex,
age
Clinical
presentation
Tumour location Tumour size Management Metastasis Outcome, follow-
up (months)
Papotti
et al.
[4]
2000
M,
65
Symptomatic
cholelithiasis
Fundus 2.5 cm CHO, Chemo NS, Partial LR Liver 4 mths after CHO Dead, 14
Jun et al.
[6]
2006
F, 67 Epigastric pain Eccentric wall
thickening with
invasion of liver
segment 4
Huge lobulated
mass
Biopsy on gallbladder and liver mass
Unresectable tumour
Chemo NS
Liver segment 6 at diagnosis Dead, 10
Jun et al.
[6]
2006
M,
55
Abdominal
discomfort and
jaundice of
4 wks' duration
Extensive wall
thickening with
necrosis and a
gallstone
Not reported Biopsy on celiac lymphnode
Unresectable tumour Chemo NS
Multiple LN (along the hepato-
duodenal ligament, celiac axis,
superior mesenteric artery, aorto-
caval, para-aortic) at diagnosis
Dead, 1
Iype et al.
[7]
2009
F, 58 18-month
history
suggestive of
gallstones
Not speciﬁed 2 cm CHO followed 2 mths later by radical
gallbladder bed clearance, liver segment
4B/5 excision, CBD excision, and LY up to
coeliac nodes
Chemo (CisP, ETP)
Regional LN Alive and well 16
mths after initial
operation
Shimono
et al.
[8]
2009
F, 64 Severe pain in
right upper
abdomen
Large mass
occupying middle
and anterior
segments of liver
11.5  10.5 cm Intra-arterial Chemo
Pre-operative 3D-RT
Right Trisegmentectomy
Post- operative Chemo (CisP, ETP)
Partial cerebellectomy
g-knife irradiation
Liver, brain Dead, 69 mths
after initial
diagnosis
3 yrs without
recurrence since
the last g-knife
irradiation
Lin et al.
[5]
2010
F, 65 Cushing's
syndrome
Body Large ACTH
producing
mass
CHO þ wedge shaped LR
Chemo refused by the pt
Liver 2 mths after surgery Dead, 2
Okuyama
et al.
[9]
2013
M,
64
Abdominal
fullness
Fundus 2.5 cm Biopsy on axillary LN and FNA of
gallbladder
Chemo (CisP,DTX,CarP)
Liver and multiple LN at diagnosis; LN,
liver, bones 22 mths after Chemo
Dead, 22
Current
report,
2015
F, 76 Abdominal pain
with clinical
history of
cholelithiasis
Fundus 1.8  1.5 cm CHO, Chemo (CisP, ETP, CarP) Regional LN and liver at diagnosis Dead, 5
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A 76-year-old Caucasian woman, non smoker, was admitted to
hospital in March 2011 with a 4 month history of intermittent
right-upper quadrant abdominal pain. As regards the past history,
the patient had undergone appendectomy 40 years previously and
had a history of acute myocardial infarction and hypertension
pharmacologically treated. There was no signiﬁcant family medical
history and her general physical examination was normal. There
were no abnormal laboratory ﬁndings. The abdominal ultraso-
nography revealed an irregular thickened gallbladder wall and a
1.8 cm gallstone, with no evidence of biliary tree dilation, of
pathological ﬁndings of the liver and ascites. The patient was
scheduled for a laparoscopic cholecystectomy. During the operation
the gallbladder appeared morphologically altered with a thickened
wall and strongly adherent to the liver bed. We proceeded to
conversion to complete cholecystectomy. The post-operative
course was uneventful and the patient was discharged on the
ﬁfth post-operative day.
At pathological examination the tumour presented as a 1.8 cm
whitish ulcerated mass in the fundus of the gallbladder. The lesion
was entirely sampled. Microscopically the tumour displayed an
insular growth pattern, often with rosette formation, entirely
composed of large cells characterized by hyperchromatic nuclei
with prominent nucleoli and a variable amount of cytoplasm. A
high mitotic rate (>20 mitotic ﬁgures/10 HPF) was noted. Lym-
phovascular and perineural invasion were identiﬁed. Foci ofintestinal metaplasia were observed in the peritumoral mucosa.
The tumour invaded the wall of the gallbladder as far as the serosa.
A metastatic 1.2 cm lymphnode in the fundus was detected.
Tumour cells were diffusely positive for pan-cytocheratin, chro-
mogranin A and synaptophysin. Ki-67 immunostain showed a 50%
proliferative rate (Figs. 1e3). The histological and immuno-
histochemical ﬁndings were consistent with a pure form of GB-
LGNEC.
After the incidental discovery of a LCNEC the patient underwent
a total body computed tomography (CT) scan. This showed several
metastatic lesions in the liver in all the segments except segment I
and segment II, with a maximum diameter of 5 cm, multiple met-
astatic lymphnodes with a maximum diameter of 2.9 cm and mild
ascites. Chromogranin A (CgA) blood levels were elevated with a
value of 1823 ng/ml (normal range < 99 ng/ml), while neuron
speciﬁc enolase (NSE) blood level was normal. The bone scan was
negative. The 111In-pentetreotide scintigraphy (Octreoscan)
showed the presence of a single hepatic lesion in segment IV.
According to guidelines [7], the patient started a ﬁrst line
chemotherapy with cisplatin and etoposide and completed a total
of two cycles. Because of kidney function impairment, cisplatinwas
substituted by carboplatin at the third cycle. The main toxicity re-
ported was a grade 4 neutropenia, well treated with granulocyte
colony stimulating factor. Somatostatin analogs were administered
in addition to chemotherapy, even if the patient did not present
carcinoid syndrome. Ten days after the last cycle of chemotherapy,
ﬁve months after the initial diagnosis she was admitted to another
Fig. 1. Macroscopic view of the tumour mass (A) and of the metastatic lymphnode (B) in the fundus of the gallbladder.
Fig. 2. Large cells arranged in an insular growth pattern deeply inﬁltrating the wall (A) Foci of intestinal metaplasia in the peritumoral mucosa (B). Evidence of vascular invasion (C).
Evidence of perineural invasion (D) (H&E, original magniﬁcations 2.5, 40, 40 and 40 respectively).
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infarction was diagnosed from which she died.
3. Discussion
The current WHO classiﬁcation divides neuroendocrine neo-
plasms of the gallbladder into the categories of NET (G1, G2),
SCNEC, LCNEC, MANEC, goblet cell carcinoid and tubular carcinoid
[3].
Primary NETs of the gallbladder are particularly rare. In the
Surveillance, Epidemiology and End Results (SEER) Program regis-
try, only 278 cases have been reported between 1973 and 2005, and
represent 0.5% of all NETs, and 2.1% of all gallbladder cancers [1].
According to the SEER registries the incidence of gallbladder NETs
(all subgroups) in the US is 0.2e0.3/100.000 [10]. In a retrospective
analysis of 25 gallbladder NETs, the age at presentation ranged from
26 to 79 years and 68% were women [11].
Primary GB-SCNEC is rare, with only 74 cases reported until2011 [12,13]. Pure GB-LCNECs are exceedingly rare and to the best
of our knowledge only 7 cases have been described in literature
(Table 1). Ours represents the eighth pure case of GB-LCNEC re-
ported. Liu et al. reported a series of 17 cases of LCNEC: 6 cases were
pure LGNECs, 11 cases were combined with other histological
components, including adeno-, adenosquamous and mucinous
carcinoma. Cases with mixed histological components were clas-
siﬁed as MANEC according to WHO 2010 [14] GB-LCNEC was ﬁrst
reported by Papotti et al., in 2000 [4]. It consists of polygonal
shaped cells that are about three times larger than small-cell type,
grows in an organoid pattern, exhibits rosetta-like areas and has
large patches of necrosis. Immunohistochemical staining shows
strong cytoplasmatic staining for neuroendocrine markers (chro-
mogranine A and synaptophysin) [6].
It is now accepted that neuroendocrine cells derive from local
multipotent gastrointestinal stem cells, rather than by migration
from the neural crest as initially proposed [15]. Neuroendocrine
cells are not present in normal gallbladder mucosa, while
Fig. 3. Massive lymphnode metastasis (A) (H&E, original magniﬁcation 10). Immunostains for chromogranin A (B) and synaptophysin (C) show diffuse cytoplasmatic positivity
(immunoperoxidase, 25 and 5 respectively). Immunostain for Ki-67 (D) shows a high proliferative rate (immunoperoxidase, x10).
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plasia, secondary to chronic inﬂammation due to cholelithiasis,
expresses a variety of different neuroendocrine cells [16]. It seems
plausible that the cell origin for gallbladder NETs may have two
sources: an undifferentiated stem cell or else a mucosal neuroen-
docrine cell in the setting of chronic inﬂammatory induced gall-
bladder epithelial metaplasia leading to malignant transformation
[2].
According to most previously reported cases of GB-LCNEC, the
clinical symptoms and radiological ﬁndings of our patient were
non-speciﬁc (Table 1). Upper abdominal pain and abdominal
discomfort were the most common symptoms (6/8, 75%). Three
patients (3/8, 37.5%) presented with a clinical history of symp-
tomatic cholecystitis and ultrasonographic demonstration of gall-
stones [4,7]. As reported, the diagnosis of gallbladder NETs is rarely
made preoperatively since the presentation generally consists of
non-speciﬁc symptoms including upper abdominal pain, discom-
fort, jaundice, weight loss. The majority of patients are identiﬁed
incidentally at the time of cholecystectomy for cholelithiasis [2].
It is not possible to differentiate preoperatively between gall-
bladder adenocarcinoma and gallbladder neuroendocrine carci-
noma (NEC) with imaging techniques. The sensitivity of
ultrasonography in the identiﬁcation of gallbladder cancer is low
accounting for 44% [17]. In our case, the abdominal ultrasonography
revealed an irregular thickened gallbladder wall and a 1.8 cm
gallstone, without the suspicion of a neoplasm.
Radiological ﬁndings of NEC have been described as a mass
replacing the gallbladder, focal or diffuse wall thickening, with or
without direct hepatic invasion, liver and lymph node metastasis
[2]. If a gallbladder tumour presents along with a large hepatic
mass and/or extensive lymphadenopathy at diagnosis, a NEC
should be considered. However, other neoplasms such as hepato-
cellular carcinoma, cholangiocarcinoma, hepatic metastasis
involving the gallbladder, gallbladder adenocarcinoma may have a
similar pattern. Moreover, Jun et al. reported no signiﬁcant differ-
ence in the CT ﬁndings of SCNEC and LCNEC of the gallbladder [6].
The only curative therapeutic modality for GB-NECs is a com-
plete en bloc surgical resection, including regional lymph nodeclearances and hepatic lobectomy, but only in patients without
multiple metastasis [18]. No rational surgical strategy currently
exists for GB-NETs for different reasons: the rarity of the disease,
the lack of predictive prognostic factors and the limited under-
standing of the biology of this tumour [2]. However, as shown in
Table 1, most of the patients had multiple metastases or direct
hepatic invasion with huge tumours at diagnosis, making them
unsuitable for surgical treatment.
The role of radiotherapy and chemotherapy in the management
of these tumours is unclear since in general NETs are insensitive to
traditional radiotherapy [19]. It seems to be that GB-NECs beneﬁt
from an aggressive surgical resection in combination with
chemotherapy, if resectability is possible [20]. If the tumour is non-
resectable, the primary management is therefore medical and not
surgical [2].
The chemotherapeutic agents recommended as the ﬁrst-line
treatment are cisplatin or carboplatin and etoposide, representing
one of the standard regimens employed for the small cell lung
cancer [21]. In our case as the treatment with cisplatin was not
tolerated, cisplatin was replaced by carboplatin at the third cycle.
Iwasa et al. showed that the ﬁrst-line chemotherapy with cisplatin
and etoposide for hepatobiliary poorly differentiated neuroendo-
crine carcinoma had only marginal antitumour activity and rela-
tively severe toxicity compared with previous studies on
extrapulmonary poorly differentiated neuroendocrine carcinoma
treated with the same regimen [21,22].
Shimono et al. reported one case of GB-LCNEC with a survival of
69 months after the initial diagnosis due to the application of a
multimodal treatment, including pre-operative intra-arterial
chemotherapy and three-dimensional radiation therapy, right tri-
segmentectomy, post-operative systemic chemotherapy and g-
knife irradiation for brain metastases [8]. This result proves that
radiation therapy is a useful modality for neoadjuvant and adjuvant
therapy in achieving local control.
Unfortunately, excluding the case of Shimono, all patients with
GB-LCNEC presented a poor prognosis with a median survival of 10
months after the initial diagnosis, as shown in Table 1. Only in ﬁve
patients (62.5%) a wide surgical excision was performed, while in
S. Buscemi et al. / International Journal of Surgery 28 (2016) S128eS132S132the other cases the tumour was non-resectable or multiple liver
metastases were present at diagnosis. Iype et al. reviewed 29 cases
of poorly differentiated GB-NECs, including 4 GB-LCNEC, and
concluded that the large-cell subtype presents a worse prognosis
than the small cell variety and chemotherapy is more effective for
SCNEC [7].
In conclusion, GB-LCNEC is extremely rare, only a few pure
cases, without combination of other histological components, are
reported in literature. An increased awareness and understanding
of the biological background of this tumour is required. Given the
lack of data, the best strategy appears to be an aggressive surgical
management, comparable to the management of the more com-
mon gallbladder adenocarcinomas. Unfortunately, tumour recur-
rence is the typical outcome and the overall survival of GB-LCNEC
remains discouraging.Ethical approval
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